What is Entresto Prescribed For?

Entresto, a brand-name medication, has become a cornerstone in the management of specific cardiovascular conditions. Unlike traditional single-ingredient drugs, Entresto is a combination therapy, integrating two distinct pharmacological agents that work synergistically to offer significant benefits to patients. Its primary indication centers on a complex and prevalent health issue: heart failure. Specifically, Entresto is prescribed for patients diagnosed with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). This condition, characterized by the heart’s reduced ability to pump blood effectively, affects millions worldwide and carries a significant burden of morbidity and mortality. Understanding the specific mechanisms and benefits of Entresto in treating HFrEF requires a deep dive into its composition and its impact on the body’s intricate compensatory systems.

Table of Contents

Understanding Heart Failure with Reduced Ejection Fraction (HFrEF)

Heart failure is a chronic, progressive condition where the heart muscle can’t pump blood as well as it should. It’s a complex syndrome that can arise from various underlying causes, including coronary artery disease, hypertension, diabetes, and valvular heart disease. When we talk about heart failure, a crucial distinction is made based on the heart’s pumping ability, often measured by the ejection fraction (EF). The ejection fraction represents the percentage of blood that the left ventricle (the main pumping chamber of the heart) pumps out with each contraction.

Reduced Ejection Fraction: A Critical Indicator

In the context of Entresto’s prescription, the focus is on heart failure with reduced ejection fraction (HFrEF). This means the left ventricle’s EF is typically at or below 40%. A normal EF is generally between 50% and 70%. When the EF is reduced, the heart struggles to deliver adequate blood flow to the body’s organs and tissues, leading to a cascade of symptoms. These symptoms can include:

Shortness of breath (dyspnea): Particularly during exertion or when lying flat (orthopnea).
Fatigue and weakness: Due to insufficient oxygen delivery to muscles.
Swelling (edema): In the legs, ankles, and feet, as fluid backs up in the circulatory system.
Rapid or irregular heartbeat (palpitations): As the heart tries to compensate for reduced pumping efficiency.
Persistent cough or wheezing: Often with the production of white or pink, blood-tinged phlegm.
Increased need to urinate at night (nocturia): Due to fluid redistribution when lying down.
Abdominal swelling (ascites) and digestive issues: As fluid accumulates in the abdominal cavity and blood flow to the gut is impaired.

HFrEF is a serious condition that significantly impacts quality of life and is associated with a high risk of hospitalizations and premature death. Effective management aims to alleviate symptoms, slow disease progression, and improve survival.

The Dual Action of Entresto: Sacubitril and Valsartan

Entresto’s efficacy stems from its innovative dual-action approach, combining two active pharmaceutical ingredients: sacubitril and valsartan. These components target specific pathways involved in the development and progression of heart failure, offering a more comprehensive therapeutic strategy than single-agent therapies.

Sacubitril: Enhancing the Body’s Protective Systems

Sacubitril is a neprilysin inhibitor. Neprilysin is an enzyme that breaks down natriuretic peptides. Natriuretic peptides are naturally occurring hormones in the body that have beneficial effects on the cardiovascular system. They help to reduce blood pressure, promote the excretion of sodium and water, and counteract the harmful effects of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), which are often overactivated in heart failure.

By inhibiting neprilysin, sacubitril increases the levels of these beneficial natriuretic peptides. This leads to:

Vasodilation: Widening of blood vessels, which reduces the workload on the heart by lowering blood pressure.
Natriuresis and Diuresis: Increased excretion of sodium and water, which helps to reduce fluid overload and congestion, common symptoms of heart failure.
Inhibition of Cardiac Remodeling: Reduced activation of the RAAS and sympathetic nervous system, which can prevent or reverse detrimental changes in the heart muscle structure that occur in heart failure.

Sacubitril is a prodrug, meaning it is inactive until it is metabolized in the body. After administration, it is converted into its active form, LBQ657, which is responsible for inhibiting neprilysin.

Valsartan: Blocking Harmful Hormonal Activity

Valsartan is an angiotensin II receptor blocker (ARB). Angiotensin II is a potent hormone that plays a central role in the RAAS. In heart failure, the RAAS becomes inappropriately activated, leading to:

Vasoconstriction: Narrowing of blood vessels, increasing blood pressure and the resistance the heart must pump against.
Sodium and Water Retention: Contributing to fluid overload and edema.
Cardiac Hypertrophy and Fibrosis: Over time, angiotensin II can promote the thickening of the heart muscle and the deposition of scar tissue, further impairing its function.

Valsartan works by blocking the action of angiotensin II at its receptor sites. This blockade prevents the harmful effects of angiotensin II, leading to:

Reduced Blood Pressure: By causing vasodilation.
Decreased Sodium and Water Retention: Helping to alleviate congestion.
Attenuated Cardiac Remodeling: Protecting the heart muscle from further damage.

The Synergy of Sacubitril and Valsartan

The combination of sacubitril and valsartan in Entresto is designed to be more effective than either component alone. Sacubitril enhances the beneficial effects of natriuretic peptides, while valsartan blocks the detrimental effects of angiotensin II. In heart failure, both the RAAS and the neurohormonal systems are dysregulated. By simultaneously targeting these pathways, Entresto offers a comprehensive approach to managing the condition. This dual blockade is believed to be more potent and effective in reducing cardiovascular events and improving survival compared to therapies that only target one of these systems.

Clinical Evidence and Benefits of Entresto

The approval of Entresto was based on robust clinical trial data demonstrating its significant impact on key cardiovascular outcomes in patients with HFrEF. The PARADIGM-HF trial was a pivotal study that compared Entresto to enalapril, a well-established ACE inhibitor, in patients with symptomatic chronic HFrEF.

Key Outcomes from PARADIGM-HF

The PARADIGM-HF trial revealed compelling results:

Reduced Cardiovascular Mortality and Hospitalization: Entresto significantly reduced the risk of death from cardiovascular causes or hospitalization for heart failure by 20% compared to enalapril. This reduction was observed across various subgroups of patients.
Lower Risk of All-Cause Mortality: The trial also showed a statistically significant reduction in the risk of death from any cause.
Improved Symptoms and Quality of Life: Patients treated with Entresto reported significant improvements in symptoms, such as shortness of breath and fatigue, and an enhanced overall quality of life.
Beneficial Hemodynamic Effects: Entresto demonstrated favorable effects on hemodynamic parameters, including reduced blood pressure and improved cardiac output.

Who Benefits Most from Entresto?

Entresto is prescribed for patients who meet specific criteria:

Symptomatic Chronic Heart Failure: Patients must have symptoms of heart failure that persist despite treatment with other standard therapies.
Reduced Ejection Fraction (HFrEF): The left ventricular ejection fraction must be at or below 40%.
Tolerance to ACE Inhibitors and ARBs (in some cases): While Entresto replaces the need for separate ACE inhibitors or ARBs, patients may have previously been on these medications. The PARADIGM-HF trial included patients who were on ACE inhibitors or ARBs or both. However, it is crucial to note that Entresto should not be initiated in patients who are currently taking an ACE inhibitor or an ARB. A washout period is required before switching to Entresto.

Entresto is typically initiated at a lower dose and gradually titrated upwards as tolerated, under the close supervision of a healthcare professional. Regular monitoring of blood pressure, kidney function, and potassium levels is essential during treatment.

Important Considerations and Precautions

While Entresto offers significant therapeutic advantages, it is essential for patients and healthcare providers to be aware of potential side effects and contraindications.

Potential Side Effects

The most common side effects associated with Entresto include:

Hypotension (Low Blood Pressure): This is a common effect due to the vasodilatory properties of the medication. Symptoms can include dizziness or lightheadedness.
Hyperkalemia (High Potassium Levels): Both valsartan and the enhanced natriuretic peptide activity can affect potassium levels. Regular monitoring of electrolytes is crucial.
Renal Impairment: Entresto can affect kidney function, particularly in patients with pre-existing kidney disease or those who are dehydrated.
Angioedema: A rare but serious allergic reaction causing swelling of the face, lips, tongue, or throat, which can be life-threatening. Patients with a history of angioedema are generally contraindicated from using Entresto.
Dizziness and Fatigue: These are often related to hypotension.

Contraindications and Warnings

Entresto is contraindicated in patients with:

History of Angioedema: Due to the potential risk of a recurrent and severe reaction.
Concomitant use with ACE Inhibitors: There is an increased risk of angioedema when sacubitril is used with an ACE inhibitor.
Hereditary Angioedema: Patients with this genetic predisposition are at a higher risk.

Entresto should be used with caution and under careful medical supervision in patients with:

Severe Renal Impairment: Dosage adjustments may be necessary.
Hepatic Impairment: Similar considerations apply to patients with liver disease.
Hypovolemia or Hyponatremia: These conditions can increase the risk of hypotension.

Pregnancy and Lactation: Entresto is contraindicated in pregnancy and during breastfeeding due to potential harm to the fetus or infant. Women of childbearing potential should use effective contraception.

In conclusion, Entresto represents a significant advancement in the management of symptomatic chronic heart failure with reduced ejection fraction. By combining sacubitril and valsartan, it effectively targets the complex neurohormonal dysregulation characteristic of this condition, leading to substantial reductions in mortality, hospitalizations, and improvements in patient well-being. Its prescription is reserved for carefully selected patients who can benefit most from its unique dual-action therapeutic profile.